RARE Daily

FDA Approves First Drug for Neurological Symptoms of Type 3 Gaucher Disease

November 19, 2026

Rare Daily Staff

The U.S. Food and Drug Administration has approved Sanofi’s Infilbray, the first medicine to treat the neurological symptoms of type 3 Gaucher disease, a rare lysosomal storage disorder that can impair thinking, coordination and balance.

The once-daily pill is approved for adults and children weighing at least 15 kilograms, or about 33 pounds. While existing enzyme replacement therapies can control the disease’s effects on organs and blood, they do not treat its neurological symptoms.

“We have been able to treat the systemic manifestations of type 3 Gaucher disease, while the neurological manifestations remained beyond the reach of available therapies,” said Pramod Mistry, director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, in Sanofi’s announcement.

Gaucher disease occurs when the body lacks enough of an enzyme needed to break down certain fatty substances. Those substances accumulate in cells, causing problems that can include enlarged organs, anemia and bone disease. In type 3, the buildup also affects the brain and nervous system, contributing to progressive neurological problems.

Infilbray works by reducing the production of the fatty substances that accumulate. Unlike enzyme replacement therapies, it can cross the blood-brain barrier, the protective boundary that restricts which substances can enter the brain.

The approval was based on a late-stage clinical trial comparing Infilbray with imiglucerase, an enzyme replacement therapy given by intravenous infusion every two weeks.

The study enrolled 43 patients aged 12 and older who had received enzyme replacement therapy for at least three years and whose non-neurological disease symptoms had stabilized. Participants were randomly assigned to receive either Infilbray and a placebo infusion or imiglucerase and a placebo pill. Neither patients nor investigators knew which treatment participants received.

After 52 weeks, Infilbray performed better on a combined statistical assessment of tests measuring coordination, balance and cognitive function, Sanofi said. The result met the study’s threshold for statistical significance.

Although the approval covers children weighing at least 15 kilograms, the pivotal trial described in the release enrolled patients aged 12 and older. Sanofi did not detail in the announcement the additional evidence supporting use in younger children.

An extension of the study, in which participants know which treatment they are receiving, is continuing.

Infilbray carries warnings about suicidal thoughts and behavior, clouding of the eye’s lens in children, and potential harm to a developing fetus.

Among the 21 patients receiving Infilbray during the study’s main analysis period, diarrhea, spleen enlargement and nausea were each reported in 14 percent. Depression, gastroenteritis and vomiting were each reported in 10 percent. In the 22-patient imiglucerase group, nausea and vomiting were each reported in 5 percent. The other listed reactions were not reported in that group. The small study groups limit comparisons of individual adverse reactions.

Aviva Rosenberg, CEO and co-founder of the Gaucher Community Alliance, described the approval as a long-awaited advance for patients whose neurological symptoms can progress during a lengthy search for a diagnosis.

“Patients living with Type 3 Gaucher disease face a long and difficult road to accurate diagnosis, often going years without answers while neurological manifestations progress,” Rosenberg said in the announcement.

Infilbray remains under regulatory review in the European Union, Japan and other jurisdictions, according to Sanofi. The company did not disclose a U.S. price or commercial availability date in its announcement.

 

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube